linjc16/ctgov huggingface dataset:
The Analgesic Effect of Nitroglycerin Patch for Postoperative Pain After Total Knee Replacement

Study Overview
=================
Brief Summary
-----------------
Patients who undergo general anestheesia for total knee arthroplasty pften have sever postoperative pain which hinders their rehabilitation. Nitroglycerin patches have been found to cause alleviation of pain especially when used in conjuction with morphine. Therefore we propose placement of a nitroglycerin patch after total kneee arthroplasty surgery and see how it affects pain scores or causes less nedd for morphine after surgery.

Detailed Description
-----------------
Patients undergoing total knee arthroplasty will be randomized into two groups: control and placebo. Eache patient will undergo total knee arthroplasty under general anesthesia. Both groups will get the same anesthetic protocal. At the end of surgery, before awakening patients will recieve either a nitroglycerin or placebo patch on their back. Both the participant and the investigator will be blinded to the group assisignment. At the end of surgery both groups will recieve morphine for postoperative pain. In the recovery room they will be given patient controlled analgesia with morphine. An investigator blinded to study assisignment will record pain scores, sedation scores, nauseau and vomiting. Patients will be given patient controlled analgesia for 24 hours and they will be followed for pain levels, morphine use, sedation and nauseau levels. The nitroderm or placebo patch will be removed after 24 hours.

Official Title
-----------------
The Analgesic Efficacy of Nitroglycerin Patches for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty

Conditions
-----------------
Total Knee Arthroplasty

Intervention / Treatment
-----------------
* Drug: Nitroderm patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy patients undergoing total knee arthroplasty Exclusion Criteria: Pshychiatric disorder Allergy to nitroglycerin or morphine Chronic renal failure Migraine headaches Hypotension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nitroderm patch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain scores |  |  | 
| morphine use |  |  | 
| sedation score |  |  | 
| nausea and vomiting |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitroglycerin, morphine, patient controlled analgesia, total knee arthroplasty
Stress Reduction for Busy Professionals

Study Overview
=================
Brief Summary
-----------------
This is a pre-post intervention pilot study to evaluate the impact of a 30-minute, 8-week mind-body/meditation intervention on self-reported quality of life in individuals employed by Allina Health. Outcomes will include validated questionnaires for depressive symptomology, perceived stress, anxiety, healthy lifestyle, quality of life as well as biological outcomes of salivary cortisol for a sub-sample of employees.

Official Title
-----------------
Pilot Study of a Brief Mind/Body Meditation Intervention for Allina Health Employees

Conditions
-----------------
Stress

Intervention / Treatment
-----------------
* Behavioral: Meditation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women aged 18 to 65 years Actively-working healthcare professional employed by Allina Health. Exclusion Criteria: Previous participation in an Allina Health stress reduction program Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 8 Week Meditation<br>Allina Health employees undergoing 8 week meditation intervention | Behavioral: Meditation<br>* 30 minute, 8 week meditation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceived stress change from baseline at week 8 | Perceived stress will be measured through the Perceived Stress Scale at baseline and week 8. | Baseline, Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Salivary Cortisol Levels Change from baseline at week 8 | Salivary samples will be obtained at baseline and week 8. | Baseline, Week 8 | 
| Lifestyle Profile change from baseline at week 8 | The Lifestyle Profile questionnaire measures self actualization, health responsibility, exercise, nutrition, interpersonal support, and stress management. It will be administered at baseline and week 8. | Baseline, Week 8 | 
| Work productivity and activity impairment change from baseline at week 8 | Work productivity and activity impairment will be measured through the WPAI:GH and will be administered at baseline and week 8. | Baseline, Week 8 | 
| Promis-29 score change from baseline at week 8 | The Promis-29 is a 29 item questionnaire measuring physical function, fatigue, pain, depression, anxiety, and social role participation. The questionnaire will be administered at baseline and week 8. | Baseline, Week 8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stress, Meditation, Mind body
Evaluation of Changes in Consumption of Drugs and Substances After Incarceration

Study Overview
=================
Brief Summary
-----------------
To improve the management and risk reduction, it is essential to understand the evolution of the consumption of psychoactive substances, medicated or not in detention; it does not have at present no data on this subject. This work has as main objective to evaluate the development of substance use terms (goods and consumption practices) by the inmates between the period preceding their incarceration and their fifth month in detention.

Official Title
-----------------
Evaluation of Changes in Consumption of Drugs and Substances After Incarceration

Conditions
-----------------
Addictions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject Subject in the fourth or fifth month of incarceration Held about agreeing to participate in the study Exclusion Criteria: Patient refusing to participate Patient unable to respond to the questionnaire (major difficulties understanding of the French language)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in practices of consumption of psychoactive substances between the period prior to incarceration and detention period | composite endpoint representing the existence of a change in practices of consumption of psychoactive substances between the period prior to incarceration and detention period | Until 5 months |
Perioperative Recovery of Moods, Opioids, and Pain Trial (PROMPT)

Study Overview
=================
Brief Summary
-----------------
The investigators aim to characterize the relationship between changes in emotional distress, opioid use, and pain throughout surgery and recovery. Additionally, the investigators aim to compare the effectiveness of post-surgical motivational interviewing and physician-guided opioid weaning vs. usual care on reducing persistent opioid use. Overall, the proposed research will advance knowledge regarding the role of psychological factors contributing to persistent opioid use after surgery.

Conditions
-----------------
Opioid Cessation

Intervention / Treatment
-----------------
* Behavioral: Motivational Interviewing and Physician Guided Opioid Weaning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18+ Undergoing a scheduled surgery English speaking Ability and willingness to complete questionnaires and assessments. Exclusion Criteria: Any conditions causing inability to complete baseline, telephone and internet assessments (e.g. education, cognitive ability, mental status, medical status)at the discretion of the investigator. Known Pregnancy Elevated Suicidality as assessed by an answer of 2 or greater on question 9 of the Beck Depression Inventory assessing suicidal thoughts. Coexisting Chronic Pain Disorder of moderate severity in area other than surgical target

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motivational Interviewing and Physician Guided Opioid Weaning<br>Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol. | Behavioral: Motivational Interviewing and Physician Guided Opioid Weaning<br> <br> |
| No Intervention: Usual Care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trial Feasibility - The proportion of people consented who complete the study in the group to which they were randomized | Factors that contribute to non-completion of the study, measured at baseline for each patient, will be analyzed. | Duration of the study - up to 2 years per participant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy - time to opioid cessation | Time to opioid cessation between the two groups will be analyzed using survival analysis | Duration of the trial - Up to 2 years per participant |
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the placement, timing, associated complications, efficacy of temporary and tunneled catheters for renal replacement therapy in patient with acute kidney injury.

Detailed Description
-----------------
The purpose of this study is to examine the placement, timing, associated complications, efficacy of temporary and tunneled catheters for renal replacement therapy in patient with acute kidney injury. In particular, we will be assessing renal replacement adequacy for patients on dialysis and continuous veno-venous hemofiltration by monitoring urea reduction ratios, venous and arterial pressures. We will also be monitoring infection rates. We will compare these outcomes in patients receiving tunneled catheters and patients receiving temporary catheters.

Official Title
-----------------
Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury- Assessment of Dialysis Adequacy and Infection Rates

Conditions
-----------------
Acute Kidney Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to the hospital with acute kidney injury requiring renal replacement therapy Exclusion Criteria: End stage renal disease Chronic kidney disease 5 progression to end stage renal disease Outside hospital catheter placement
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dialysis adequacy | Adequacy will be measured using urea reduction ratio for patients on intermittent hemodialysis. For continuous renal replacement therapy, we will record the maximum blood flow rate achievable. These measurements/recordings will be made on average within 1-3 days of starting therapy. | up to 7d after starting renal replacement therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood stream infection rates | Patients will be followed throughout their hospitalization, which can range from a few days to several weeks. Bloodstream infections within 30d of catheter placement will be recorded. | within 30d of catheter placement |
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

Official Title
-----------------
Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage

Conditions
-----------------
Acquired Bleeding Disorder, Intracerebral Haemorrhage

Intervention / Treatment
-----------------
* Drug: activated recombinant human factor VII


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Spontaneous intracranial haemorrhage (ICH) within 3 hours after first symptom Exclusion Criteria: Patients with secondary ICH Pre-existing disability Haemophilia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: activated recombinant human factor VII|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing haematoma growth |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing disability and improving clinical outcome |  |  |
Dexamethasone and Dexmedetomidine as an Adjuvant to Spinal Anesthesia for Elective Caesarean Sections

Study Overview
=================
Brief Summary
-----------------
The main objective of our study is to evaluate analgesic effect of intrathecal dexamethasone and dexmedetomidine in elective caesarean sections

Official Title
-----------------
Comparison Between Analgesic Effect of Dexamethasone and Dexmedetomidine as an Adjuvant to Bupivacaine for Spinal Anesthesia for Elective Caesarean Sections

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: Intrathecal dexamethasone
* Drug: Intrathecal dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists classII-III adult female patient (age :18 -40 years old ) Elective cesarean section under spinal anaesthesia Gestational age > 37 weeks BMI less than 30 kg/m2 Exclusion Criteria: Patient refusal unable to give consent age < 18 or > 40 BMI more than 30 kg/m2 known allergy to the study medication coagulopathies or on anticoagulant medications diabetic neuropathy patients with psychiatric disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: dexamethasone intrathecal<br> | Drug: Intrathecal dexamethasone<br>* intrathecal adjuvants to bupivacaine<br>|
| Active Comparator: dexmedetomidine intrathecal<br> | Drug: Intrathecal dexmedetomidine<br>* intrathecal adjuvants to bupivacaine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analgesic effect | Duration of sensory block and time to first analgesic rescue . . | Up to 24 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraoperative complications | Incidince of intraoperative shivering, nausea and vometing | during surgery |
The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants

Study Overview
=================
Brief Summary
-----------------
Music has been consistently shown to reduce stress and increase weight gain in premature infants. The mechanism of this presumed improved metabolic efficiency is unknown. We aim to test the hypothesis that music by Mozart reduces energy expenditure in growing healthy preterm infants.

Official Title
-----------------
The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants

Conditions
-----------------
Preterm Infants

Intervention / Treatment
-----------------
* Other: music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: appropriate weight for gestational age postmenstrual age of 30-37 weeks gavage fed tolerating full enteral feedings without significant gastric residuals (>5% of total feed) no electrolyte imbalance Exclusion Criteria: congenital anomalies dysmorphism intracranial hemorrhage of any grade periventricular leukomalacia necrotizing enterocolitis supplemental oxygen requirements by 28 days of age or by 36 weeks of postmenstrual age and at least 1 week prior to measurement active infection patent ductus arteriosus apnea of prematurity

Ages Eligible for Study
-----------------
Maximum Age: 60 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: music therapy<br>Each infant was randomized to receive music therapy or no music over 2 consecutive days | Other: music<br>* Each infant was randomized to receive music therapy or no music over 2 consecutive days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy Expenditure (EE) |  | during measurment of EE | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolic rate, music, preterm infants, energy expenditure, NIDCA
Enthesitis in Patients With Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The current study was conducted to estimate the prevalence of knee cap enthesitis in patients with knee osteoarthritis and its relation to knee function.

Detailed Description
-----------------
The current study will based on a cross sectional hospital-based survey, conducted among patients with knee osteoarthritis , Knee will assessed for the following items in both sides while Patient lying supine with the knee flexed 40 degrees: Superior pole of the patella - quadriceps tendon enthesis: ● Quadriceps tendon thickness >6.1 mm ● Suprapatellar bursitis ● Superior pole of patella erosion ● Superior pole of patella enthesophyte. Inferior pole of the patella - proximal patellar ligament enthesis: ● Patellar ligament thickness >4 mm ● Inferior pole of patella erosion ● Inferior pole of patella enthesophyte. Tibial tuberosity - distal patellar ligament enthesis ● Patellar ligament thickness >4 mm ● Infrapatellar bursitis ● Tibial tuberosity erosion ● Tibial tuberosity enthesophyte. Knee functional status was assessed using Knee injury and Osteoarthritis Outcome Score (KOOS) scale for Pain, other Symptoms, Activities of Daily Living (ADL), Sport and Recreation Function (Sport/Rec) and knee-related Quality of Life (QOL). Low knee function was considered if the patient had score 50 or more in any KOOS scale parameter.

Official Title
-----------------
Prevalence of Knee Cap Enthesitis in Patients With Knee Osteoarthritis, Cross Sectional Ultrasonographic Study.

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary Knee OA diagnosed according to: American College of Rheumatology Radiologic Criteria for Knee Osteoarthritis. Kellegren - Lawrance scale grade II. On regular treatment by analgesics, or NSAIDS either topical or systemic. Exclusion Criteria: Recent Knee trauma or intra-articular procedures. Previous knee surgery. Inflammatory joint diseases, as rheumatoid arthritis, crystal arthritis, and spondyloarthropathy chronic systemic diseases that could affect patient functional ability; e.g renal, liver, cardiac impairment, or neurological disorder.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of knee cap enthesitis in patients with knee osteoarthritis | Detection of the prevalence | two months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
enthesitis, osteoarthritis, ultrasound